BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 9816280)

  • 1. Preclinical antitumor activity of bizelesin in mice.
    Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
    Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
    Fujimoto K; Oka T; Morimoto M
    Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
    Watanabe M; Komeshima N; Nakajima S; Tsuruo T
    Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
    Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.
    Finch RA; Shyam K; Penketh PG; Sartorelli AC
    Cancer Res; 2001 Apr; 61(7):3033-8. PubMed ID: 11306484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of 2-chloroethyl (methylsulfonyl)methanesulfonate (clomesone, NSC 33847) against selected tumor systems in mice.
    Dykes DJ; Waud WR; Harrison SD; Laster WR; Griswold DP; Shealy YF; Montgomery JA
    Cancer Res; 1989 Mar; 49(5):1182-6. PubMed ID: 2537144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
    Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.
    Li LH; DeKoning TF; Kelly RC; Krueger WC; McGovren JP; Padbury GE; Petzold GL; Wallace TL; Ouding RJ; Prairie MD
    Cancer Res; 1992 Sep; 52(18):4904-13. PubMed ID: 1516047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
    McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
    Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.
    Pierré A; Kraus-Berthier L; Atassi G; Cros S; Poupon MF; Lavielle G; Berlion M; Bizzari JP
    Cancer Res; 1991 May; 51(9):2312-8. PubMed ID: 2015595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.
    Waud WR; Leopold WR; Elliott WL; Dykes DJ; Laster WR; Temple CG; Harrison SD; Griswold DP
    Cancer Res; 1990 Jun; 50(11):3239-44. PubMed ID: 2334919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
    Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
    Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors.
    Plowman J; Harrison SD; Dykes DJ; Paull KD; Narayanan VL; Tobol HK; Martin J; Griswold DP
    Cancer Res; 1989 Apr; 49(8):1909-15. PubMed ID: 2702634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
    Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
    Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.
    Dexter DL; Hesson DP; Ardecky RJ; Rao GV; Tippett DL; Dusak BA; Paull KD; Plowman J; DeLarco BM; Narayanan VL
    Cancer Res; 1985 Nov; 45(11 Pt 1):5563-8. PubMed ID: 4053030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
    Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
    Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical antitumor activity of penclomedine in mice: cross-resistance, schedule dependence, and oral activity against tumor xenografts in brain.
    Harrison SD; Plowman J; Dykes DJ; Waud WR; Griswold DP
    Cancer Res; 1991 Apr; 51(8):1979-83. PubMed ID: 2009516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
    Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
    Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.